Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Other Accumulated Expenses (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Other Accumulated Expenses for 5 consecutive years, with $218000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 12.37% to $218000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $218000.0, a 12.37% increase, with the full-year FY2025 number at $218000.0, up 12.37% from a year prior.
  • Other Accumulated Expenses was $218000.0 for Q4 2025 at Ekso Bionics Holdings, down from $244000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $256000.0 in Q2 2023 to a low of $97000.0 in Q2 2024.
  • A 4-year average of $168666.7 and a median of $157000.0 in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 62.11% in 2024, then soared 106.78% in 2025.
  • Ekso Bionics Holdings' Other Accumulated Expenses stood at $161000.0 in 2022, then fell by 9.94% to $145000.0 in 2023, then surged by 33.79% to $194000.0 in 2024, then grew by 12.37% to $218000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Other Accumulated Expenses are $218000.0 (Q4 2025), $244000.0 (Q3 2025), and $153000.0 (Q2 2025).